Ignite Creation Date:
2024-05-06 @ 11:02 AM
Last Modification Date:
2024-10-26 @ 12:39 PM
Study NCT ID:
NCT03416699
Status:
UNKNOWN
Last Update Posted:
2018-01-31
First Post:
2018-01-01
Brief Title:
Chinese TaTME Registry Collaborative
Sponsor:
Beijing Friendship Hospital
Organization:
Beijing Friendship Hospital
Study Overview
Official Title:
Chinese Transanal Total Mesorectal Excision Registry Collaborative A Nationwide Registry Study
Status:
UNKNOWN
Status Verified Date:
2018-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Total mesorectal excision TME is the gold standard procedure for treating rectal cancer However in patients with obesity prostate hypertrophy low located tumor orand pelvic stenosis the traditional laparoscopic or open surgery is not easy to conduct Transanal total mesorectal excision TaTME might serve as a better procedure for these patients for it might ease the dissection of the low mesorectum So far several studies have showed the promising results of TaTME but the multi-center data in China is still lacking This nationwide registry study included more than 30 Chinese hospitals aiming at obtaining data on the safety and efficacy of this procedure in Chinese patients with rectal cancer and encouraging future research in this field
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None